MDEV - ETF AI Analysis
Top Page
First Trust Indxx Medical Devices ETF (MDEV)
MDEV, the First Trust Indxx Medical Devices ETF, has a solid but not top-tier rating, suggesting it offers a balanced mix of strengths and risks in the medical devices space. Strong contributors like Dexcom, Thermo Fisher, Agilent, and Waters support the fund with robust financial performance and positive growth outlooks, while weaker holdings such as Baxter International and Bio-Rad Laboratories, which face financial and operational challenges, likely weigh on the overall rating and highlight the risk of owning companies with leverage, profitability, and cash flow issues within this specialized sector.
MDEV vs. SPDR S&P 500 ETF (SPY)
- AUM
- 3.32M
- Region
- Global
- Expense Ratio
- 0.70%
- Beta
- 0.72
- Issuer
- First Trust
- Inception Date
- Jun 22, 2021
- Dividend Yield
- 0.10%
- Asset Class
- Equity
- Index Tracked
- Indxx Global Medical Equipment Index
MDEV Summary
MDEV is the First Trust Indxx Medical Devices ETF, which follows the Indxx Global Medical Equipment Index. It invests in companies that make medical devices used in hospitals and clinics, from diagnostic tools to surgical equipment. The fund holds well-known names like Stryker and Philips, giving you a way to invest in the growth of health care technology and to diversify beyond general stock market funds. However, because it focuses mainly on medical device companies, its value can go up and down with changes in the health care sector.
How much will it cost me?
MDEV has an annual expense ratio of 0.70%, which means you’ll pay about $7 per year for every $1,000 invested. This cost is higher than the average ETF because it’s a specialized, passively managed fund focused on a niche area of the health care sector, which typically comes with higher fees than broad market index ETFs.
What would affect this ETF?
This global medical devices ETF could benefit from aging populations, rising health care spending, and ongoing innovation at companies like Stryker, Philips, and Cochlear, which may drive demand for equipment used in diagnostics and surgery. On the downside, changes in health care regulations, pricing pressures from insurers and governments, and economic slowdowns that cause hospitals to delay equipment purchases could weigh on future performance.
MDEV Top 10 Holdings
MDEV is a pure play on global medical technology, with heavy exposure to U.S. and international health care equipment names. Rising stars like Revvity, Agilent, and Thermo Fisher are doing much of the heavy lifting, supported by steady contributions from West Pharmaceutical and Waters. On the flip side, Baxter looks like a weak link, with financial and technical headwinds, while Sysmex and Dexcom show more mixed, stop‑and‑go momentum. Overall, the fund leans into innovative diagnostics and devices, but a few laggards are quietly tugging on returns.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 AU:COH | Cochlear | 2.22% | $73.77K | AUD 9.60B | -49.61% | 69Neutral |
 GB:SN | Smith & Nephew | 2.20% | $73.07K | GBP 9.65B | -16.27% | 70Outperform |
 COO | Cooper Co | 2.17% | $71.98K | $11.64B | -17.86% | 77Outperform |
 SYK | Stryker | 2.14% | $70.95K | $117.81B | -19.82% | 70Outperform |
 CH:STMN | Straumann Holding AG | 2.14% | $70.93K | CHF 15.77B | 10.65% | 72Outperform |
 ZBH | Zimmer Biomet Holdings | 2.13% | $70.77K | $18.80B | -4.46% | 73Outperform |
 NL:PHIA | Koninklijke Philips N.V. | 2.13% | $70.71K | EUR 23.41B | -2.82% | 56Neutral |
 PODD | Insulet | 2.12% | $70.48K | $10.33B | -53.93% | 70Outperform |
 RMD | Resmed | 2.12% | $70.30K | $35.56B | -4.67% | 76Outperform |
MDEV Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MDEV, the sentiment is Positive. The current price of 22.01 is above the 20-day moving average (MA) of 21.10, above the 50-day MA of 21.00, and above the 200-day MA of 19.99, indicating a bullish trend. The MACD of 0.30 indicates Negative momentum. The RSI at 70.42 is Negative, neither overbought nor oversold. The STOCH value of 100.12 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MDEV.
MDEV Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| MDEV | $22.01 | $22.00(-0.03% Downside) | $3.32M | 0.70% | 64Neutral |
 OZEM | $29.64 | $47.13(59.01% Upside) | $56.01M | 0.59% | 55Neutral |
 HRTS | $37.46 | $44.95(20.01% Upside) | $55.93M | 0.75% | 67Neutral |
 FMED | $31.54 | $43.58(38.17% Upside) | $51.44M | 0.50% | 59Neutral |
 PSIL | $20.64 | $54.49(164.01% Upside) | $45.18M | 1.00% | 45Neutral |
 MEDI | $33.54 | $44.57(32.88% Upside) | $43.16M | 0.80% | 62Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MDEV | First Trust Indxx Medical Devices ETF | 22.01 | 0.92 | 4.36% | |
| OZEM | Roundhill GLP-1 & Weight Loss ETF | 29.64 | 2.02 | 7.33% | |
| HRTS | Tema Cardiovascular and Metabolic ETF | 37.46 | 5.21 | 16.16% | |
| FMED | Fidelity Disruptive Medicine ETF | 31.54 | 4.78 | 17.85% | |
| PSIL | AdvisorShares Psychedelics ETF | 20.64 | 2.29 | 12.48% | |
| MEDI | Harbor Health Care ETF | 33.54 | 3.35 | 11.11% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.